Max HealthcareQ1 FY27
Max Healthcare Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,016P/E: 65.0Market Cap: ₹97.3K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Continued capacity expansion across key locations (Lucknow, Noida, Nagpur) leading to higher occupancy and revenue growth.
- →New brownfield capacity additions expected to contribute directly to bottom-line profitability.
- →Incremental beds being added at Nanavati and Max Smart, with occupancy ramping up to around 80%, suggesting strong revenue and EBITDA growth potential.
- →Commissioning of new hospital beds phased over quarters, with EBITDA impact expected from Q2-Q3 onward.
- →Long-term outlook supports steady ARPOB growth of 7-8%, outpacing inflation due to innovation and novel treatments.
- →Institutional revenue share expected to decline gradually due to changing mix.
- →Planned capital expenditure on new hospital towers (e.g., Max Vaishali) enhancing bed capacity before FY30.
- →Expansion into medical education business anticipated to generate new revenue streams in the coming years.
Margin guidance
Category 3- →Revenue growth momentum remains strong with 16% year-on-year growth in Q1 FY27.
- →Operating EBITDA grew by 15% year-on-year, indicating healthy profit growth.
- →Incremental beds being added at Nanavati and Max Smart are expected to start contributing EBITDA steadily, with Max Smart beds already at 80% occupancy.
- →No significant increase in operating expenses expected until Gurugram project comes up, leading to higher EBITDA flow-through.
- →Net debt-to-EBITDA ratio is below 1 and expected to remain controlled; debt may marginally increase due to ongoing capex but should reduce in medium term.
- →Oncology segment expected to normalize from Q3 FY27 onwards, supporting revenue and profit growth.
- →ARPOB (Average Revenue per Occupied Bed) growth of 5-9% is expected to continue.
- →Expansion and acquisitions—such as Max Bhubaneswar—are gradually integrated, contributing to future earnings.
- →Medical education business with ROCE >25% is a new growth avenue, funded via internal accruals, slated to start operations in coming years.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company currently has net debt-to-EBITDA below 1 and is comfortable increasing it up to 2.5x for acquisitions or other purposes.
- →There is an ongoing capex plan, including projects like Shaheed Path with INR 425 crore approval.
- →The company expects to fund medical education expansion entirely through internal accruals.
- →Net debt may marginally increase by the end of the year due to ongoing capex and potential loans to finance projects.
- →Management indicates that over the next 3-4 years, capex will be funded and debt will be paid down.
- →No explicit mention of immediate equity fundraising; focus is on internal accruals and debt within manageable limits.
Order book
The transcript does not explicitly mention any current or expected order book or pending orders for Max Healthcare Institute Limited. The discussion mainly centers around operational capacity expansion, regulatory approvals, and project timelines for new hospitals and expansions, including:
- Ongoing brownfield capacity expansions in Lucknow, Noida, and Nagpur with positive ramp-up.
- Multiple bed additions planned across locations such as Vaishali, Bhubaneswar, Nagpur, Zirakpur, Dwarka, Pitampura, Patparganj, Nanavati, and Pune with commissioning dates through FY29 and FY30.
- For Thane and Shaheed Path projects, regulatory approvals are underway with delivery expected 30-36 months after approvals (approximately after six months).
- Expansion projects are proceeding as scheduled; no mention of formal orders or contracts backlog is given.
Thus, the focus is on organic capacity build-out and regulatory progress rather than listing specific pending orders or an order book.
Capex plans
Yes- →Approved capex of INR 425 crore for a new brownfield tower at Max Vaishali adding 202 beds; construction started, commissioning expected before FY30.
- →Ongoing capacity expansions include:
- → - 100 beds at Max Lucknow (commissioning next two quarters)
- → - 500 beds at Sector 56 Gurgaon (phased commissioning from end of this year)
- → - 250 beds at Bhubaneswar (renovations to complete within 12 months)
- → - 100 beds at Nagpur (commissioning by FY28)
- → - 400 beds at Zirakpur, Mohali (commissioning in FY28)
- → - Onco day care block at Max Dwarka (awaiting occupancy certificate)
- → - 260 beds at Dwarka (commission by FY30)
- → - 200 beds at Pitampura (commission by FY29)
- → - 400 beds at Patparganj (work started, commissioning by end FY29)
- → - 271 beds at Nanavati Phase 2 (commission by FY30)
- → - 450 beds at Pune (IOD received, commissioning by FY30)
- →Plans to start medical education business with significant capex (~INR 300 crore per 150-seat college) funded through internal accruals.
How does Max Healthcare rank vs peers in Healthcare Services?
Pro feature1Max Healthcare
Rev 3Mar 3
See full Healthcare Services sector rankings
How does Max Healthcare rank in Healthcare Services?
Compare Max Healthcare against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.